Indivior (NASDAQ:INDV) Shares Gap Down – Should You Sell?

Shares of Indivior PLC (NASDAQ:INDV) gapped down before the market opened on Thursday . The stock had previously closed at $9.44, but opened at $7.85. Indivior shares last traded at $7.87, with a volume of 726,133 shares.

Analyst Ratings Changes

INDV has been the topic of several research analyst reports. Craig Hallum decreased their price target on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Piper Sandler restated an “overweight” rating and set a $15.00 target price (down previously from $22.00) on shares of Indivior in a research note on Friday.

Indivior Stock Down 6.5 %

The firm has a market cap of $1.03 billion, a price-to-earnings ratio of 746.00 and a beta of 0.68. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The stock has a 50-day moving average of $11.11 and a 200-day moving average of $14.80.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The business had revenue of $299.00 million during the quarter, compared to the consensus estimate of $285.90 million. Sell-side analysts predict that Indivior PLC will post 1.7 EPS for the current fiscal year.

Institutional Trading of Indivior

A number of institutional investors and hedge funds have recently made changes to their positions in INDV. Bank of New York Mellon Corp bought a new position in Indivior in the second quarter valued at approximately $188,000. VELA Investment Management LLC bought a new position in shares of Indivior in the 2nd quarter valued at $235,000. XTX Topco Ltd acquired a new position in shares of Indivior during the 2nd quarter worth $249,000. Cubist Systematic Strategies LLC lifted its position in shares of Indivior by 32.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after buying an additional 6,121 shares during the last quarter. Finally, Cannon Global Investment Management LLC acquired a new stake in Indivior in the first quarter valued at about $563,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.